| Literature DB >> 36092788 |
Qingzhu Zhang1,2, Yinhui Yao3, Jinzhu Wang2, Yufeng Chen1, Dong Ren1, Pengcheng Wang1.
Abstract
Objective: To explore the influencing factors of knee osteoarthritis (KOA) severity and establish a KOA nomogram model.Entities:
Mesh:
Year: 2022 PMID: 36092788 PMCID: PMC9462991 DOI: 10.1155/2022/3605369
Source DB: PubMed Journal: Comput Math Methods Med ISSN: 1748-670X Impact factor: 2.809
Demographics and clinical characteristics of 400 patients with knee osteoarthritis in the training cohort.
| Variables | Total ( | KL 1-3 ( | KL 4 ( |
|
|---|---|---|---|---|
| Sex, n (%) | 0.19 | |||
| Female | 290 (72) | 143 (69) | 147 (76) | |
| Male | 110 (28) | 63 (31) | 47 (24) | |
| Age, median (Q1, Q3) | 64 (58, 69) | 60 (54.25, 65) | 66 (63, 71) | <0.001 |
| Height, median (Q1, Q3) | 160 (158, 167) | 162 (158, 168) | 160 (158, 165) | 0.147 |
| Weight, median (Q1, Q3) | 70 (60, 75) | 70 (62, 80) | 69 (60, 75) | 0.061 |
| Physical illnesses, | <0.001 | |||
| No | 152 (38) | 96 (47) | 56 (29) | |
| Yes | 248 (62) | 110 (53) | 138 (71) | |
| Temperature, median (Q1, Q3) | 36.4 (36.2, 36.6) | 36.3 (36.2, 36.6) | 36.4 (36.2, 36.5) | 0.635 |
| Pulse, median (Q1, Q3) | 80 (74, 88) | 80 (72, 87) | 82 (74.5, 90) | 0.004 |
| Breathing rate, | 0.77 | |||
| 16 | 34 (8) | 16 (8) | 18 (9) | |
| 18 | 256 (64) | 135 (66) | 121 (62) | |
| 20 | 110 (28) | 55 (27) | 55 (28) | |
| Systolic pressure, median (Q1, Q3) | 141 (130, 157) | 138 (128, 150) | 146 (132.25, 160) | 0.003 |
| Diastolic pressure, mean ± SD | 83.05 ± 11.83 | 82.71 ± 12.06 | 83.41 ± 11.61 | 0.555 |
| C-reactive protein, median (Q1, Q3) | 1.68 (0.81, 3.95) | 1.68 (0.83, 3.62) | 1.74 (0.8, 4.3) | 0.462 |
| White blood cell count, median (Q1, Q3) | 5.64 (4.75, 6.49) | 5.64 (4.79, 6.42) | 5.65 (4.72, 6.64) | 0.807 |
| Red blood cell count, median (Q1, Q3) | 4.33 (4.09, 4.65) | 4.39 (4.13, 4.71) | 4.24 (3.99, 4.56) | <0.001 |
| Haemoglobin, median (Q1, Q3) | 132 (123, 142) | 134 (127, 144) | 128 (120.25, 138) | <0.001 |
| Haematocrit, median (Q1, Q3) | 40 (37.9, 42.73) | 40.65 (38.52, 43.18) | 39.4 (37.25, 42.08) | <0.001 |
| Platelet count, mean ± SD | 225.93 ± 54.4 | 224.91 ± 52.99 | 227 ± 55.97 | 0.702 |
| Neutrophil ratio, mean ± SD | 58.04 ± 8.96 | 57.21 ± 9.15 | 58.91 ± 8.69 | 0.057 |
| Lymphocyte percentage, mean ± SD | 31.36 ± 7.9 | 32.29 ± 8.05 | 30.38 ± 7.63 | 0.015 |
| Monocyte percentage, median (Q1, Q3) | 7.4 (6.4, 8.6) | 7.3 (6.4, 8.6) | 7.5 (6.5, 8.78) | 0.285 |
| Percentage of eosinophils, median (Q1, Q3) | 2 (1.2, 3.1) | 2.05 (1.2, 3) | 2 (1.2, 3.1) | 0.937 |
| Percentage of basophils, median (Q1, Q3) | 0.5 (0.4, 0.7) | 0.5 (0.4, 0.7) | 0.5 (0.4, 0.7) | 0.337 |
| Absolute value of neutrophils, median (Q1, Q3) | 3.16 (2.59, 3.93) | 3.1 (2.63, 3.75) | 3.34 (2.55, 4.09) | 0.184 |
| Absolute value of lymphocytes, median (Q1, Q3) | 1.71 (1.38, 2.12) | 1.78 (1.43, 2.17) | 1.67 (1.35, 2.05) | 0.043 |
| Absolute value of monocytes, median (Q1, Q3) | 0.42 (0.34, 0.5) | 0.41 (0.34, 0.49) | 0.42 (0.34, 0.51) | 0.236 |
| Absolute value of eosinophils, median (Q1, Q3) | 0.11 (0.07, 0.17) | 0.11 (0.07, 0.17) | 0.11 (0.06, 0.18) | 0.845 |
| Absolute value of basophils, median (Q1, Q3) | 0.03 (0.02, 0.04) | 0.03 (0.02, 0.04) | 0.03 (0.02, 0.04) | 0.486 |
| Average volume of red blood cells, median (Q1, Q3) | 92.8 (89.8, 95.7) | 92.5 (90.23, 94.97) | 93.05 (89.5, 96) | 0.382 |
| Average haemoglobin content, median (Q1, Q3) | 30.6 (29.58, 31.6) | 30.9 (29.8, 31.8) | 30.45 (29.2, 31.4) | 0.011 |
| Mean corpuscular haemoglobin concentration(MCHC), median (Q1, Q3) | 329 (322, 336) | 332 (324.25, 338) | 325.5 (320, 333) | <0.001 |
| Coefficient of the variation of red blood cell distribution width, median (Q1, Q3) | 12.6 (12.1, 13.1) | 12.5 (12, 13) | 12.6 (12.12, 13.2) | 0.003 |
| Red blood cell distribution width -SD value, median (Q1, Q3) | 42.9 (41, 44.9) | 42.2 (40.8, 44.4) | 43.45 (41.73, 45.5) | <0.001 |
| Average volume of platelets, median (Q1, Q3) | 10.3 (9.7, 11) | 10.3 (9.6, 11) | 10.3 (9.9, 11) | 0.258 |
| Distribution width of platelets, median (Q1, Q3) | 11.7 (10.6, 13.4) | 11.7 (10.5, 13.4) | 11.7 (10.8, 13.35) | 0.537 |
| Ratio of large platelets, median (Q1, Q3) | 27.25 (22.4, 33.32) | 27.25 (21.83, 33.27) | 27.2 (23.58, 33.25) | 0.377 |
| Thrombocytocrit, median (Q1, Q3) | 0.23 (0.2, 0.26) | 0.23 (0.2, 0.26) | 0.24 (0.2, 0.27) | 0.505 |
| Total protein, median (Q1, Q3) | 68.1 (64.65, 71.6) | 67.95 (65.2, 71.75) | 68.15 (63.9, 71.38) | 0.53 |
| Albumin, median (Q1, Q3) | 38.8 (37, 40.73) | 39.2 (37.4, 41.08) | 38.4 (36.6, 40.48) | 0.006 |
| Total bilirubin, median (Q1, Q3) | 11.77 (9.44, 14.66) | 12.41 (9.72, 14.98) | 11.22 (9.13, 14) | 0.034 |
| Prealbumin, median (Q1, Q3) | 250.45 (213.75, 287.82) | 254.1 (216.4, 291.65) | 241.7 (208.62, 284.35) | 0.093 |
| Alanine aminotransferase, median (Q1, Q3) | 15 (11.2, 21.38) | 15.4 (11.25, 21.28) | 14.1 (11.12, 21.48) | 0.244 |
| Aspartate aminotransferase, median (Q1, Q3) | 19.1 (16.28, 23.4) | 19.35 (16.83, 23.4) | 18.9 (16.1, 23.37) | 0.542 |
| Gamma glutamyltransferase, median (Q1, Q3) | 22.05 (15.9, 34.45) | 21.75 (15.72, 33.6) | 22.55 (16.52, 35.55) | 0.496 |
| Direct bilirubin, median (Q1, Q3) | 3.3 (2.5, 4.2) | 3.5 (2.5, 4.38) | 3.2 (2.4, 4) | 0.151 |
| Alkaline phosphatase, median (Q1, Q3) | 82.2 (69.7, 98.1) | 76.85 (67.53, 91.95) | 86.55 (72.9, 103.6) | <0.001 |
| Blood glucose, median (Q1, Q3) | 4.99 (4.55, 5.65) | 4.96 (4.58, 5.57) | 5.02 (4.52, 5.83) | 0.922 |
| Total cholesterol, median (Q1, Q3) | 4.63 (4.12, 5.35) | 4.62 (4.16, 5.43) | 4.64 (4.05, 5.3) | 0.366 |
| Triglyceride, median (Q1, Q3) | 1.4 (1.05, 2.01) | 1.38 (1.04, 1.97) | 1.41 (1.11, 2.07) | 0.373 |
| High-density lipoprotein cholesterol, median (Q1, Q3) | 1.21 (1.04, 1.4) | 1.23 (1.04, 1.44) | 1.17 (1.02, 1.36) | 0.207 |
| Apolipoprotein A1, median (Q1, Q3) | 1.19 (1.08, 1.33) | 1.21 (1.07, 1.37) | 1.18 (1.08, 1.3) | 0.493 |
| Apolipoprotein B, median (Q1, Q3) | 0.88 (0.76, 1.04) | 0.89 (0.76, 1.03) | 0.88 (0.75, 1.05) | 0.952 |
| Low-density lipoprotein cholesterol, median (Q1, Q3) | 2.83 (2.46, 3.27) | 2.83 (2.48, 3.28) | 2.83 (2.4, 3.26) | 0.562 |
| Potassium, median (Q1, Q3) | 3.68 (3.45, 3.89) | 3.74 (3.46, 3.92) | 3.63 (3.44, 3.81) | 0.026 |
| Sodium, median (Q1, Q3) | 141 (139, 142) | 140 (139, 141) | 141 (139, 142) | 0.019 |
| Chlorine, median (Q1, Q3) | 106 (105, 108) | 106 (105, 108) | 106 (105, 108) | 0.439 |
| Calcium, mean ± SD | 2.26 ± 0.1 | 2.27 ± 0.1 | 2.25 ± 0.1 | 0.193 |
| Phosphorus, median (Q1, Q3) | 1.12 (1, 1.26) | 1.11 (1, 1.24) | 1.12 (0.99, 1.28) | 0.777 |
| Magnesium, median (Q1, Q3) | 0.88 (0.83, 0.91) | 0.87 (0.82, 0.9) | 0.88 (0.83, 0.92) | 0.344 |
|
| 152 (135, 172.25) | 147 (131, 169) | 154.5 (138, 174.75) | 0.004 |
| Lactic dehydrogenase, median (Q1, Q3) | 178 (157, 200.25) | 172.5 (152, 198) | 183 (163, 203) | 0.006 |
| Creatine kinase, median (Q1, Q3) | 63.5 (48.68, 85.1) | 63.5 (49.92, 83.38) | 63.55 (47.12, 87.68) | 0.721 |
| Creatine kinase isoenzyme, median (Q1, Q3) | 12 (9.75, 15) | 12 (9, 15) | 12 (10, 15) | 0.571 |
| Blood urea nitrogen (BUN), median (Q1, Q3) | 5.36 (4.48, 6.42) | 5.12 (4.3, 5.94) | 5.64 (4.7, 6.83) | < 0.001 |
| Creatinine, median (Q1, Q3) | 56.7 (50.35, 66.3) | 56.95 (50.2, 67.22) | 56.4 (50.5, 66.25) | 0.98 |
| Uric acid, median (Q1, Q3) | 296.25 (248.43, 361.6) | 296.6 (250.3, 362.03) | 295.45 (245.6, 359.1) | 0.928 |
| Bicarbonate, mean ± SD | 25.88 ± 2.23 | 25.83 ± 2.32 | 25.94 ± 2.13 | 0.627 |
|
| 1.63 (1.44, 1.91) | 1.53 (1.39, 1.78) | 1.72 (1.53, 2.06) | <0.001 |
| Homocysteine determination, median (Q1, Q3) | 13.1 (11.38, 16.5) | 12.5 (10.9, 16.28) | 13.75 (11.9, 16.6) | 0.007 |
| Lipoprotein A, median (Q1, Q3) | 13.05 (6.68, 28.23) | 11.65 (5.62, 26.82) | 14.75 (7.53, 29.23) | 0.077 |
| Serum cystatin C determination, median (Q1, Q3) | 0.64 (0.55, 0.77) | 0.6 (0.52, 0.7) | 0.67 (0.59, 0.8) | <0.001 |
| Adenosine deaminase, median (Q1, Q3) | 9.85 (8.5, 11.9) | 9.55 (8.3, 11.7) | 10.1 (8.7, 12.2) | 0.079 |
| Serum total bile acid, median (Q1, Q3) | 3.5 (2.2, 5.7) | 3.45 (2.2, 5.77) | 3.6 (2.2, 5.5) | 0.918 |
| Estimated glomerular filtration rate, median (Q1, Q3) | 98.42 (90.7, 104.56) | 101.78 (94.04, 108.55) | 95.36 (87.9, 100.53) | <0.001 |
| Fibrinogen, median (Q1, Q3) | 2.57 (2.25, 2.96) | 2.49 (2.26, 2.94) | 2.62 (2.24, 2.96) | 0.309 |
| Prothrombin time, median (Q1, Q3) | 11.2 (10.8, 11.7) | 11.2 (10.8, 11.7) | 11.2 (10.8, 11.8) | 0.693 |
| Thrombin time, median (Q1, Q3) | 17.7 (17.1, 18.5) | 17.7 (17.1, 18.6) | 17.7 (17.1, 18.3) | 0.276 |
| Activity, mean ± SD | 93.33 ± 8.61 | 93.52 ± 8.17 | 93.12 ± 9.08 | 0.64 |
| International standardized ratio, median (Q1, Q3) | 0.97 (0.94, 1.02) | 0.97 (0.94, 1.02) | 0.97 (0.93, 1.03) | 0.666 |
| Activated partial thromboplastin time, mean ± SD | 26.08 ± 2.08 | 26.14 ± 2.12 | 26.02 ± 2.04 | 0.563 |
| Fibrinogen degradation products, median (Q1, Q3) | 2.5 (2.5, 2.5) | 2.5 (2.5, 2.5) | 2.5 (2.5, 2.5) | 0.103 |
| Antithrombin III, median (Q1, Q3) | 87.7 (81.57, 97.73) | 87.75 (81.95, 97.18) | 87.7 (81.08, 97.85) | 0.935 |
| Erythrocyte sedimentation rate, median (Q1,Q3) | 10 (6, 17) | 9 (5, 15) | 12 (6, 18) | 0.004 |
| Blood type ABO, | 0.766 | |||
| AB | 35 (9) | 20 (10) | 15 (8) | |
| A | 134 (34) | 72 (35) | 62 (32) | |
| B | 115 (29) | 57 (28) | 58 (30) | |
| O | 116 (29) | 57 (28) | 59 (30) | |
| Blood type Rh, | 1 | |||
| Negative | 2 (0) | 1 (0) | 1 (1) | |
| Positive | 398 (100) | 205 (100) | 193 (99) |
Figure 1Prediction factors for osteoarthritis severity were selected, and an osteoarthritis severity nomogram was developed in patients with knee osteoarthritis in the training cohort. (a, b) Least absolute shrinkage and selection operator (LASSO) coefficient profiles of the 14 prediction factors. (c) Logistic regression analyses of the 5 prediction factors in patients with knee osteoarthritis. (d) Nomogram prediction of osteoarthritis severity in patients with knee osteoarthritis.
Figure 2Evaluation of the KOA nomogram and its clinical use in patients with KOA in the training cohort. (a) ROC curve based on the predictive nomogram for osteoarthritis severity. (b) Calibration plots for predicting osteoarthritis severity. (c) Decision curve analysis for the osteoarthritis severity nomogram in patients with knee osteoarthritis. (d) Clinical impact plot for predicting osteoarthritis severity.
Figure 3Evaluation of the KOA nomogram and its clinical use in patients with KOA in the validation cohort. (a) Nomogram prediction of osteoarthritis severity in patients with knee osteoarthritis. (b) ROC curve based on the predictive nomogram for osteoarthritis severity. (c) Calibration plots for predicting osteoarthritis severity. (d) Decision curve analysis for the osteoarthritis severity nomogram in patients with knee osteoarthritis. (e) Clinical impact plot for predicting osteoarthritis severity.
Figure 4Correlation analysis of nomogram-related markers and osteoarthritis severity.